



## **Evolocumab is initiated in Central and Eastern Europe at much higher LDL-C levels than recommended in guidelines: Results from the observational HEYMANS study**

V. Blaha<sup>1</sup>, R. Margoczy<sup>2</sup>, I. Petrov<sup>3</sup>, A. Postadzhiyan<sup>4</sup>, K. Raslova<sup>5</sup>, H. Rosolova<sup>6</sup>, I. Bridges<sup>7</sup>, NN. Dhalwani<sup>8</sup>, M. Zachlederova<sup>9</sup>, KK. Ray<sup>10</sup>

*(1) University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czechia (2) Middle Slovak Institute of Cardiovascular Diseases, Banska Bystrica, Slovakia (3) University Hospital Acibadem City Clinic and Sofia University "St. Kliment Ohridski", Sofia, Bulgaria (4) Medical University of Sofia, Sofia, Bulgaria (5) Slovak Medical University, National Reference Centre for Familial Hyperlipoproteinemias, Bratislava, Slovakia (6) Charles University of Pilsen, Center of Preventive Cardiology, Pilsen, Czechia (7) Amgen UK Ltd, Uxbridge, United Kingdom of Great Britain & Northern Ireland (8) Amgen Inc., Thousand Oaks, United States of America (9) Amgen s.r.o., Prague, Czechia (10) Imperial College London, London, United Kingdom of Great Britain & Northern Ireland*

**Objectives:** We examined clinical characteristics and LDL-C lowering in patients initiating evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the pan-European HEYMANS study.

**Materials and Methods:** Patients from Bulgaria, Czech Republic, and Slovakia were enrolled at initiation of evolocumab (baseline) as per local reimbursement criteria. Demographic/clinical characteristics, lipid lowering therapy (LLT) and lipid values were collected from medical records for ≤6 months before baseline and ≤30 months after evolocumab initiation.

**Results:** Overall, 333 patients were followed over a mean (SD) duration of 25.1 (7.5) months. Of 333 patients, 48% received evolocumab monotherapy, while approx. one-quarter received evolocumab with statin and ezetimibe combination, and the rest with statin or ezetimibe alone. Median (Q1, Q3) baseline LDL-C was 4.7 (4.0, 5.9) mmol/L and fell by 58% to 2.1 (1.3, 2.9) mmol/L by month 3, a reduction sustained over time (30-month LDL-C: 2.1 [1.5, 2.9] mmol/L). Achievement of the ESC/EAS LDL-C goal of <1.4 mmol/L was 50% overall and 59% when evolocumab/oral LLT combination was used. At 12-months and 30-months, 94% (304/324) and 93% (180/193) received evolocumab, respectively.

**Conclusion:** In the HEYMANS CEE cohort, patients initiated on evolocumab had baseline LDL-C levels >3x higher than guideline-recommended thresholds for PCSK9i initiation. Therefore, only half of patients achieved the goal of LDL-C <1.4 mmol/L. However, evolocumab use was associated with a substantial and sustained LDL-C reduction of >50%. Lowering the LDL-C reimbursement threshold for PCSK9i initiation would allow more patients to receive combination therapy, thus improving LDL-C goal attainment.